68Ga-PSMA PET-CT in biochemical relapse following primary treatment of Prostate Carcinoma (PCa)

Not Applicable

Recruiting

• Conditions: Recurrent Prostate Carcinoma; Cancer - Prostate

• Registration Number: ACTRN12615000608561
• Lead Sponsor: Sir Charles Gairdner Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-06-11
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

Histologically confirmed prostate carcinoma
Initial biochemical relapse following definitive treatment (Surgery or XRT) for prostate carcinoma or biochemical relapse at least 6 months following previous systemic (hormonal) treatment. (Biochemical relapse defined as PSA>0.2ng/mL at >6 weeks post radical prostatectomy or a PSA level 2 ng/mL above the previous PSA nadir measured >3 months after external beam radiotherapy-EBRT).
Standard staging imaging, bone scan and abdominal CT, performed within 4 weeks of referral, showing no or oligometastatic disease. (Oligometastatic disease includes up to a maximum of four lesions.)
No other active neoplastic disease
Able to undergo study procedures / treatment
Able to provide informed consent

Exclusion Criteria

Disseminated prostate carcinoma
Hormone refractory prostate carcinoma

Study & Design

• Study Type: Interventional
• Study Design: Not specified